{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T09:10:05Z","timestamp":1759914605989,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1016\/j.maturitas.2008.03.004","type":"journal-article","created":{"date-parts":[[2008,5,10]],"date-time":"2008-05-10T05:37:47Z","timestamp":1210397867000},"page":"71-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Oral contraceptives, salpingo-oophorectomy and hormone replacement therapy in BRCA1\u20132 mutation carriers"],"prefix":"10.1016","volume":"60","author":[{"given":"N.","family":"Biglia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Ponzone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Sismondi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.maturitas.2008.03.004_bib1","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S0140-6736(94)91578-4","article-title":"Risks of cancer in BRCA1-mutation carriers","volume":"343","author":"Ford","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2008.03.004_bib2","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.maturitas.2008.03.004_bib3","first-page":"265","article-title":"Breast and ovarian cancer incidence in BRCA1-mutation carriers breast cancer linkage consortium","volume":"56","author":"Easton","year":"1995","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.maturitas.2008.03.004_bib4","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1002\/cncr.21367","article-title":"Is BRCA1\/BRCA2-related breast carcinogenesis estrogen dependent?","volume":"104","author":"Nourizinia","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.maturitas.2008.03.004_bib5","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/00001648-200105000-00010","article-title":"Oral contraceptives, other methods of contraception, and reduced risk for ovarian cancer","volume":"12","author":"Ness","year":"2001","journal-title":"Epidemiology"},{"key":"10.1016\/j.maturitas.2008.03.004_bib6","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/ijc.10696","article-title":"Long-term effects of oral contraceptives on ovarian cancer risk","volume":"102","author":"Bosetti","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1016\/j.maturitas.2008.03.004_bib7","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(08)60167-1","article-title":"Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23.257 women with ovarian cancer and 87.303 controls","volume":"371","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2008.03.004_bib8","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJM199808133390702","article-title":"Oral contraceptives and the risk of hereditary ovarian cancer","volume":"339","author":"Narod","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.maturitas.2008.03.004_bib9","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/sj.bjc.6602239","article-title":"Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations","volume":"91","author":"Whittemore","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.maturitas.2008.03.004_bib10","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/aje\/kwh284","article-title":"Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations","volume":"160","author":"McGuire","year":"2004","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.maturitas.2008.03.004_bib11","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJM200107263450401","article-title":"Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation","volume":"345","author":"Modan","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.maturitas.2008.03.004_bib12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S1470-2045(06)70983-4","article-title":"Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case\u2013control study","volume":"8","author":"McLaughlin","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.maturitas.2008.03.004_bib13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/oxfordjournals.epirev.a036115","article-title":"Reproductive factors and breast cancer","volume":"15","author":"Kelsey","year":"1993","journal-title":"Epidemiol Rev"},{"key":"10.1016\/j.maturitas.2008.03.004_bib14","first-page":"1713","article-title":"Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer form 54 epidemiological studies","volume":"346","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2008.03.004_bib15","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1158\/1055-9965.EPI-04-0376","article-title":"Oral contraceptive use and risk of early onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations","volume":"14","author":"Milne","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.maturitas.2008.03.004_bib16","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1093\/jnci\/94.23.1773","article-title":"Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"94","author":"Narod","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.maturitas.2008.03.004_bib17","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1158\/1055-9965.EPI-06-0258","article-title":"BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50","volume":"15","author":"Haile","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.maturitas.2008.03.004_bib18","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1200\/JCO.2007.11.1179","article-title":"Oral contraceptives and breast cancer risk in the international BRCA1\/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group","volume":"25","author":"Brohet","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2008.03.004_bib19","doi-asserted-by":"crossref","first-page":"397","DOI":"10.7326\/0003-4819-144-6-200603210-00006","article-title":"Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation","volume":"144","author":"Anderson","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.maturitas.2008.03.004_bib20","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/ijc.22817","article-title":"Effectiveness of preventive interventions in BRCA1\/2 gene mutation carriers: a systematic review","volume":"121","author":"Bermejo-P\u00e9rez","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.maturitas.2008.03.004_bib21","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1200\/JCO.2007.11.3449","article-title":"Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2","volume":"25","author":"Kauff","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2008.03.004_bib22","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1200\/JCO.2004.04.033","article-title":"Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"22","author":"Metcalfe","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2008.03.004_bib23","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1056\/NEJMoa012158","article-title":"Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations","volume":"346","author":"Rebbeck","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.maturitas.2008.03.004_bib24","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","article-title":"Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2","volume":"302","author":"King","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.maturitas.2008.03.004_bib25","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1054\/bjoc.2000.1407","article-title":"Prevalence of penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases","volume":"83","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/j.maturitas.2008.03.004_bib26","first-page":"3776","article-title":"Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations","volume":"8","author":"Satagopan","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1016\/j.maturitas.2008.03.004_bib27","doi-asserted-by":"crossref","first-page":"7491","DOI":"10.1200\/JCO.2004.00.7138","article-title":"Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case\u2013control study","volume":"20","author":"Eisen","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2008.03.004_bib28","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1200\/JCO.2003.04.131","article-title":"Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations","volume":"21","author":"Levine","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2008.03.004_bib29","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1006\/gyno.1998.5267","article-title":"Carcinoma of the fallopian tube: a clinicopathological study of 105 cases with observations on staging and prognostic factors","volume":"72","author":"Alvarado-Cabrero","year":"1999","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.maturitas.2008.03.004_bib30","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","article-title":"Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women's health initiative randomized controlled trial","volume":"291","author":"Anderson","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2008.03.004_bib31","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2008.03.004_bib32","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ygyno.2006.08.004","article-title":"The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations A prospective study","volume":"104","author":"Beiner","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.maturitas.2008.03.004_bib33","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ygyno.2005.06.009","article-title":"BRCA2 germline mutation in a woman with uterine serous papillary carcinoma\u2014case report","volume":"99","author":"Lavie","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.maturitas.2008.03.004_bib34","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1001\/jama.295.17.2057","article-title":"Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis","volume":"295","author":"Nelson","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2008.03.004_bib35","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1200\/JCO.1997.15.3.969","article-title":"Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer","volume":"15","author":"Loprinzi","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2008.03.004_bib36","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.2005.05.1896","article-title":"The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy","volume":"24","author":"Madalinska","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2008.03.004_bib37","doi-asserted-by":"crossref","first-page":"7804","DOI":"10.1200\/JCO.2004.00.8151","article-title":"Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group","volume":"23","author":"Rebbeck","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2008.03.004_bib38","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1200\/JCO.2004.06.090","article-title":"Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1\/2 mutations: a decision analysis","volume":"22","author":"Armstrong","year":"2004","journal-title":"J Clin Oncol"}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512208001059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512208001059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T08:44:49Z","timestamp":1759913089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512208001059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["S0378512208001059"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2008.03.004","relation":{},"ISSN":["0378-5122"],"issn-type":[{"type":"print","value":"0378-5122"}],"subject":[],"published":{"date-parts":[[2008,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral contraceptives, salpingo-oophorectomy and hormone replacement therapy in BRCA1\u20132 mutation carriers","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2008.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}